Australia markets close in 6 hours

ASLAN Pharmaceuticals Limited (ASLN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.0800+0.0100 (+0.93%)
At close: 04:00PM EST
1.0800 0.00 (0.00%)
After hours: 07:40PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.0700
Open1.0700
Bid1.0300 x 800
Ask1.0800 x 2200
Day's range1.0300 - 1.0800
52-week range1.0200 - 6.7500
Volume175,957
Avg. volume411,733
Market cap75.187M
Beta (5Y monthly)2.33
PE ratio (TTM)N/A
EPS (TTM)-0.4880
Earnings date26 Oct 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
  • GlobeNewswire

    ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

    - Data from Phase 1b dose escalation cohorts to be presented during the 2022 Winter Clinical Dermatology Conference, held in-person from 14-19 January, 2022, in Koloa, Hawaii - Data will also be presented as an encore presentation at the MauiDerm Conference, held in-person and virtually from 24-28 January, 2022, in Maui, Hawaii MENLO PARK, Calif. and SINGAPORE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical company de

  • GlobeNewswire

    ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022

    MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022. An on demand recording of the presen

  • GlobeNewswire

    ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

    MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decent